Capital World Investors Bei Gene, Ltd. Transaction History

Capital World Investors

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $279 Million - $347 Million	-1,828,239 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $197 Million - $280 Million	1,292,029 Added 240.96%	1,828,239 $281 Million
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $52.2 Million - $95 Million	536,210 New	536,210 $90.1 Million

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.1B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.